Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312 · View on ClinicalTrials.gov ↗
Study Summary
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG VVD-130037
Study Locations (20)
Other
- National Cancer Center — Goyang
- Gachon University Gil Medical Center — Incheon
- Seoul National University; Bundang Hospital — Seongnam
- Asan Medical Center — Seoul
- Samsung Medical Center — Seoul
- Seoul National University Hospital — Seoul
- Severance Hospital; Yonsei University Health System — Seoul
- The Catholic University of Korea, St. Vincent's Hospital — Suwon
- Hospital Vall d'Hebron — Barcelona
- START Barcelona Hospital HM Nou Delfos — Barcelona
- Hospital Universitario 12 de Octubre — Madrid
- Hospital Universitario Ramon y Cajal — Madrid
Florida
- Mayo Clinic Jacksonville — Jacksonville
- Florida Cancer Specialists — Sarasota
- Moffitt Cancer Center — Tampa
Texas
- MDACC — Houston
- NEXT Dallas — Irving
Minnesota
- Mayo Clinic Rochester — Rochester
Tennessee
- Sarah Cannon Research Institute — Nashville
Virginia
- NEXT Virginia — Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05954312
The ClinicalTrials.gov registry entry for NCT05954312 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vividion Therapeutics, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05954312 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Other, Florida, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05954312 about?
NCT05954312 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors". A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
What is the current status of trial NCT05954312?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2023-07-28. Estimated completion is 2031-02-28.
What conditions does trial NCT05954312 study?
This clinical trial studies the following conditions: Advanced Solid Tumors. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05954312?
The interventions under investigation include: Pembrolizumab (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), VVD-130037 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05954312?
This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05954312 being conducted?
This trial has 20 study locations across Florida, Minnesota, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.